Please assess the completion status of the following clinical trial:

Trial Title: Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Either of the following: Mild Diabetes Mellitus or Stress Hyperglycemia~* AND:~* Cardiac Surgery~* Insulin Requirement between 8-30 units subcutaneous on post-op day 3 or later off pressors, off enteral feeding, extubated OR glucose \>150 mg/dL at least twice in a 24 hour period (\>4 hours apart) and otherwise not requiring basal insulin~Exclusion Criteria:~* use of pressors, mechanical ventilation, or enteral or parenteral feeding within previous 12 hours~* glucocorticoids in doses exceeding the equivalent of Prednisone 10 mg/day within the previous 48 hours~* left ventricular assist device~* percutaneous or laparoscopic surgery~* end stage renal disease~* end stage liver disease~* history of pancreatitis~* type 1 diabetes~* pregnancy~* unable to give consent in english~* no phone~* prisoners~* less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo prior to discharge and 6 weeks after discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).